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Abstract
Background: The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly
prolonged survival of patients, but relapses are common and are normally associated with increased resistance. To
elucidate the mechanisms responsible for cytarabine resistance, and to create a tool for drug discovery investigations,
we established a unique and molecularly reproducible cytarabine resistant model from the Z138 MCL cell line.
Methods: Effects of different substances on cytarabine-sensitive and resistant cells were evaluated by assessment of
cell proliferation using [methyl-14C]-thymidine incorporation and molecular changes were investigated by protein and
gene expression analyses.
Results: Gene expression profiling revealed that major transcriptional changes occur during the initial phase of
adaptation to cellular growth in cytarabine containing media, and only few key genes, including SPIB, are deregulated
upon the later development of resistance. Resistance was shown to be mediated by down-regulation of the
deoxycytidine kinase (dCK) protein, responsible for activation of nucleoside analogue prodrugs. This key event,
emphasized by cross-resistance to other nucleoside analogues, did not only effect resistance but also levels of SPIB and
NF-κB, as assessed through forced overexpression in resistant cells. Thus, for the first time we show that regulation of
drug resistance through prevention of conversion of pro-drug into active drug are closely linked to increased
proliferation and resistance to apoptosis in MCL. Using drug libraries, we identify several substances with growth
reducing effect on cytarabine resistant cells. We further hypothesized that co-treatment with bortezomib could prevent
resistance development. This was confirmed and show that the dCK levels are retained upon co-treatment, indicating a
clinical use for bortezomib treatment in combination with cytarabine to avoid development of resistance. The
possibility to predict cytarabine resistance in diagnostic samples was assessed, but analysis show that a majority of
patients have moderate to high expression of dCK at diagnosis, corresponding well to the initial clinical response to
cytarabine treatment.
Conclusion: We show that cytarabine resistance potentially can be avoided or at least delayed through co-treatment
with bortezomib, and that down-regulation of dCK and up-regulation of SPIB and NF-κB are the main molecular events
driving cytarabine resistance development.
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Background
Mantle cell lymphoma (MCL) is an aggressive B-cell
lymphoma, molecularly defined by the translocation of
CCND1 [1]. The malignant cells harbor a number of
molecular abbreviations such as overexpression of SOX11
[2] and constitutive activation of the nuclear factor-κB
(NF-ĸB) pathway [3]. The NF-ĸB pathway regulates a
number of genes involved in apoptosis, cell adhesion, pro-
liferation and tissue remodeling. Especially, relapsed MCL
has increased activity of the pathway which most likely
has a key role in maintaining tumour cell viability and
drug resistance, through overexpression of several anti-
apoptotic proteins [4, 5].
Traditionally, MCL was characterized by initial sensi-
tivity to standard chemotherapy followed by relapse, and
unfavorable outcome [6, 7]. However, addition of high-
dose cytarabine treatment as part of the induction
therapy has resulted in great improvement in survival in
subgroups of MCL patients [8]. Cytarabine (ara-C, cyto-
sine arabinoside) is a deoxycytidine nucleoside analogue,
an S-phase specific anti-metabolite, which is used in
modern MCL combinatorial treatment protocols [9].
High-dose cytarabine is effective due to the improved re-
tention of ara- CTP by target cells [10], but likewise
toxic, causing mainly hematological side effects. Thus,
understanding the molecular mechanism(s) responsible
for resistance, identifying predictive markers for
resistance and/or sensitizing agents, would be of great
clinical value.
Cytarabine is a prodrug, which first needs to be trans-
ported across the plasma membrane, and secondly be-
come activated through phosphorylation. Transportation
of nucleosides and nucleoside analogues across the
plasma membrane is mediated by transporter proteins
belonging to the solute carrier families 28 and 29
(SLC28 and SLC29). SLC28 genes encode the three
members of the concentrative nucleoside transporter
(CNT) family, while the four members of equilibrative
nucleoside transporter (ENT) proteins are encoded by
SLC29 genes [11]. Both ENT and CNT recognise most
of the nucleoside analogues used for cancer therapy and
as such they are interesting targets for further studies.
For most of the nucleoside analogues commonly used
for anti-cancer therapy, the first phosphorylation step is
catalysed by deoxycytidine kinase (dCK). Both de novo
resistance and acquired resistance to cytarabine, includ-
ing cross-resistance to other nucleoside analogues, have
been linked to down-regulation of dCK on gene and
protein level [12–14].
Today, there are many treatment alternatives available
for relapsed or recurrent MCL patients but only little in-
formation available on which patients that would benefit
from each alternative. Thus, the aims of the present
study were to (i) characterize the mechanisms of
cytarabine resistance in MCL, (ii) identify drugs suitable
for treatment of relapsed/recurrent MCL patients treated
with Ara-C and (iii) to suggest preventive measurements
based on in vitro-model data.
To do so we have established a unique MCL resistant
model in which cytarabine resistance repetitively and mo-
lecularly reproducibly can be induced in a highly con-
trolled manner. Using molecular profiling, we show that
down-regulation of the dCK protein is key to development
of resistance. The cellular model, representing three stages
of resistance development (naïve sensitive, exposed sensi-
tive and resistant) was further characterized using gene
expression analysis and functional analysis. Key gene
changes, including upregulation of the transcription factor
SPIB was identified. We further show that similar to
relapsed/recurrent MCLs, the resistant cells are not only
defined by the lack of dCK and increased SPIB, but also
high levels of NF-κB.
Functional screens using (i) chemotherapeutics or (ii)
epigenetic regulators were used to identify drugs with
potential cross-resistance and/or sensitivity, and to select
individual epigenetic candidate drugs for sensitisation of
cytarabine-resistant cells. Co-treatment with bortezomib
and cytarabine prevented resistant development, but
could not overcome resistance once dCK was abolished.
The importance of dCK for response to therapy was
confirmed by the analysis of primary MCLs where 97% of
the patients have high or intermediate dCK at diagnosis.
Methods
Cell culture
The MCL cell line Z138 was purchased from ATCC
(Manassas, VA, USA). Both untreated and resistant cell
lines were cultured in R10 medium (RPMI 1640
(HyClone Laboratories, Logan, UT, USA) supplemented
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA,
USA) and 1% 2 mM L-glutamine (Invitrogen)).
Reagents
Cytarabine (147–94-4, Pfizer, New York, NY, USA) was ali-
quoted and stored at 4 °C with bulk concentrations of
411 mM. SCREEN-WELL® Epigenetics library (BML-2836,
Enzo LifeSciences Inc., Farmingdale, NY, USA) and
Chemotherapeutic Agent Library (L1500, Selleck, Munich,
Germany) were stored at − 80 °C until use. Substances
used for proliferation studies including bortezomib (2204S,
Cell Signaling Technologies), lenalidomide (PCID-216326
Santa Cruz Biotechnology, USA), apicidin (A8851, Sigma
Aldrich), belinostat (PXD101), M-344 (M5820, Sigma
Aldrich), oxamflatin (O3139, Sigma Aldrich, St. Louis,
MO, USA), scriptaid (S7817, Sigma Aldrich), trichostatin A
(T1952, Sigma Aldrich) and vorinostat (SAHA MK0683,
Selleck) were dissolved in DMSO (Sigma Aldrich), ali-
quoted and stored at − 80 °C until use.
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Establishment of resistant sub-clones
The first resistant sub-clone defined as Z138 Cytarabine
Resistant (Z138-CytR) was established by continuous ex-
posure of wild type Z138 Cytarabine Naïve Sensitive
cells (Z138-CytNS) to increasing concentrations (0.005–
0.3 μM) of cytarabine. Using this model, we could iden-
tify the approximate time to resistance development,
and utilize this information for developing a novel time-
controlled cytarabine resistant model, described below.
Z138-CytNS, with viability above 85%, were ex-
posed to 0.005 μM cytarabine and kept at log phase
(1–2 × 106 cells/ml). Concentrations were increased
two- or ten-fold, and samples for immunoblotting were
taken when viability reached above 85%. When reaching a
concentration of 0.2 μM cytarabine, cells were expanded
and frozen as a cell biobank, a sub-clone called Z138
Cytarabine Exposed Sensitive (Z138-CytES). This cell
biobank could then be used for further cytarabine expos-
ure experiments and the establishment of a Cytarabine
Resistant 21 days (Z138-CytR21) sub-clone.
Effect of cytarabine on sensitive and resistant cell lines
Cells were seeded in a 48 well plate and incubated with
0, 0.5, 5 and 50 μM of cytarabine at 37 °C (5% CO2) for
24–96 h. Duplicates from each concentration were
counted in an automatic cell counter (Countess™,
Invitrogen) at each time point, and trypan blue exclusion
method was used to monitor viability.
Assessment of cell proliferation by [methyl-14C]-thymidine
incorporation
Cells were seeded in a Cytostar-T 96 well plate (Perkin
Elmer, Waltham, MA, USA) and cultured for up to 72 h
in presence of 0.5 μCi/ml [methyl-14C]-thymidine
(PerkinElmer). Cell proliferation was measured at
indicated time-points using a Wallac 1450 MicroBeta
liquid scintillation counter (Perkin Elmer). Prior to all
measurements, cells were centrifuged to allow contact to
the scintillation liquid.
Re-introduction of dCK into dCK negative resistant cells
To assess the importance of dCK in relation to resist-
ance, the protein was transiently re-introduced into re-
sistant cells. The Amaxa protocol (Amaxa Biosystems
Cologne, Germany) for nucleofection of suspension cell
lines was followed, using program CM-138 and Cell Line
Nucleofector Solution SF (Amaxa Biosystems). For the
re-introduction experiments, 2.5 × 106 cells were mixed
with 2 μg of OmicsLink™Expression Clone for dCK
(EX-C0081-M46, vector information can be found in
Additional file 1) in each reaction and a GFP vector was
used as a positive control (both from GeneCopoeia,
Germantown, MD, USA).
Gene expression analysis
Triplicate cultures of cells were harvested at different
time-points and lysed in TRIzol (Invitrogen). Preparation
of tRNA was performed as previously described [15].
Gene expression was assessed using Affymetrix Human
Transcriptome Array 2.0 (HTA 2.0; Affymetrix Inc., Santa
Clara, CA, USA), and acquired data was pre- processed at
the SCIBLU Genomics Centre (Lund University, Sweden)
involving quality control and normalization, using the
Expression Console software (Affymetrix Inc). Normalized
and log2 transformed data was imported into Qlucore
Omics Explorer 3.0 (Qlucore AB, Lund, Sweden) for
statistical analysis. For confirmation of mRNA expression
in different samples, TaqMan probe-based RT-PCR was
performed, using TaqMan® Fast Universal PCR Master
Mix (Applied Biosystem, Waltham, MA, USA) and the
TaqMan assay Hs01040726_m1 (dCK, Applied Biosystem)
and Hs00162150_m1 (SPIB, Applied Biosystem). 18S
(Hs99999901_s1, Applied Biosystem) was used as
reference gene. All data were analyzed using the 7500
software v2.0.5 (Applied Biosystem). Functional annota-
tion of individual genes was obtained from NCBI/Gene
(http://www.ncbi.nlm.nih.gov/gene), GeneCards (http://
www.genecards.org/) or UniProt (http://www.uniprot.org/).
Library preparation, hybridization capture and MPS
sequencing
DNA from Z138-CytNS, Z138-CytES and Z138-CytR
cells were purified using RNeasy Plus Mini Kit (Qiagen,
Hilden, Germany) and thereafter quantified using the
Qubit system (Life Technologies, Carlsbad, CA, USA).
Two μg of DNA were fragmented using the Covaris S2
Ultrasonicator (Covaris, Woburn, MA, USA) and DNA
fragments from 64 target genes, including TP53 were
captured using SureselectXT Custom 3–5.9 Mb library
kit (Agilent Technology, Santa Clara, CA, USA). Before
capture, eight samples were pooled, and the molarity of
the pooled library was determined based on and DNA
fragment size distribution measured on a Bioanalyzer
(Agilent) and concentration measured by Qubit. Sequen-
cing was performed on the Illumina HiSeq 2500 (Illumina,
San Diego, CA, USA) with 2 × 101 bp paired end reads.
Analysis of sequencing data
Picard Extract IlluminaBarcodes and IlluminaBasecallsTo-
Sam (https://broadinstitute.github.io/picard/) was used for
format conversion and demultiplexing of raw Illumina
sequencing data and sequence reads were aligned to the hu-
man reference genome hs37d5ss (1000 genome with decoy
sequences) using Novoalign (http://www.novocraft.com).
Picard MarkDuplicates were used to identify and exclude
PCR duplicates in subsequent analyses and quality scores
were recalibrated and indels realigned using the Genome
Analysis Tool Kit (GATK) [16]. GATK UnifiedGenotyper
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with a call confidence cutoff of 10 were used to identify
genetic variants and genotypes. Variants were annotated
for their effect on protein coding transcripts using snpEff
and Annovar using RefSeq reference transcripts. Bases of
coding exons and 20 bp of adjacent introns were covered
by at least 30 reads and variants affecting coding
exons and 20 bp of adjacent introns were evaluated
for pathogenicity.
Silencing of SPIB in the resistant cell line
Cell Line Nucleofector Solution SF was used with pro-
gram CM-138 following the Amaxa protocol for suspen-
sion cell lines (Amaxa Biosystems). Cells were mixed
with 1000 nM of siRNA (Ambion, Austin, TX, USA) or
a scrambled sequence. GFP-producing plasmid was used
as control for the transfections (Amaxa Biosystems).
Effect of bortezomib on resistance development
Based on the set up presented above, Z138-CytES cells
were co-treated with 0.3 μM of cytarabine and 0.001 or
0.01 μM of bortezomib during the 21 days expected for
resistance to develop. A positive control with only 0.3 μM
of cytarabine was grown in parallel (as visualized in
Fig. 10c). Z138-CytNS cells and Z138-CytR cells were
subjected to the same treatment during the same period.
Lysates for immunoblotting were sampled continuously
during the treatment period and after completed treat-
ment. After 21 days of treatment, proliferation in cytara-
bine containing medium was assessed by [methyl-14C]-
thymidine incorporation as previously described.
Immunoblotting
Cells were harvested for western blot and lysed on ice
with lysis buffer (1% NP40 (Sigma Aldrich) in PBS
supplemented with 1× complete protease inhibitor
(Roche Applied Sciences, Indianapolis, IN, USA)) for
30 min followed by centrifugation at 4 °C, 1300 rpm for
additional 30 min. Supernatants consisting of protein ly-
sates were collected and protein concentrations were
measured using a bicinchoninic acid kit (Sigma Aldrich).
For western blot, 25 μg protein was loaded on a Bis-Tris
gel (Life Technologies, Carlsbad, USA). Following elec-
trophoresis using an XCell Surelock Mini- Cell system
(Life Technologies), the proteins were immediately blotted
onto a PVDF membrane using program P3 on the iBlot
Dry Blotting System (Life Technologies). The membranes
were then blocked for 60 min with 5% milk in PBS, before
incubation with primary antibodies targeting dCK
(TA502698, OriGene Technologies, Rockville, MD, USA),
ENT1 (ab 11,337–1-AP, Proteintech, Chicago, IL, USA),
SPIB (Cell Signaling), NF- κB (D14E12, Cell Signaling),
IκBα (44D4, Cell Signaling) and/or GAPDH (G8795, Sigma
Aldrich). Horseradish peroxidase-conjugated rabbit anti-
mouse immunoglobulin (P0260, Dako, Glostrup, Denmark)
and swine anti-rabbit immunoglobulin (P0217, Dako)
were used as secondary antibodies. Protein levels were
visualized in a ChemiDoc™ MP Imaging System (Bio-Rad
Laboratories, Hercules, CA, USA) with SuperSignal West
Femto Maximum Sensitivity Substrate (ThermoFisher
Scientific). Quantification of the results was performed
using the Image Lab software (Version 5.2.1, Bio-Rad
Laboratories).
Screening of compound libraries and validation of
selected drugs
Z138-CytNS or Z138-CytR cells were seeded in a
Cytostar-T 96 well plate as previously described, and
treated with different concentrations of chemotherapeu-
tic and epigenetic drugs. Non-treated cells re-suspended
in R10 medium were considered as R10 controls, and
DMSO (0.01%) treated cells as vehicle controls. Prolifer-
ation was measured 0, 24 and 48 h after addition of che-
motherapeutic and/or epigenetic drugs. To evaluate the
additive effect of epigenetic drugs to cytarabine, 50 μM
cytarabine was added 6 h after pre-incubation of cells
with epigenetic compounds.
Patients, cohorts and treatment protocols
Materials from patients included in the Nordic Lymph-
oma Group MCL2 and MCL3 trials at hospitals in
Sweden, Finland, Norway and Denmark, were selected
for TMA construction as previously described [17]. The
treatment protocols for MCL2 and MCL3 both include
high-dose cytarabine, rituximab and ASCT as previously
described [9].
Immunohistochemistry staining and digital scoring
Immunohistochemistry was performed as previously
described [2]. The sections were stained for dCK
(TA502698; OriGene Technologies) and visually ana-
lysed using a Nikon ECLIPSE 80i microscope (Nikon
Instruments Inc., Melville, NY, USA) at a magnification
of 20× (Plan Flour 20× DIC M/N2, Nikon) with a
numeric aperture of 0.5. Images were captured using a
Nikon DS-U2/L2 USB (Nikon) camera, and NIS Elements
BR 3.10 (Nikon) as acquisition software. For digital scor-
ing, dCK stained slides were scanned at an absolute mag-
nification of 20× (resolution of 0.493 μm per pixel) and
digitally scored using HALO™ (Indica Labs, Corrales, NM,
USA). Positive areas (tumour) and negative areas (stroma)
were separated and quantified based on a pattern recogni-
tion algorithm in the HALO platform. Image analysis
based on RGB (red, green, blue) spectra was used to detect
all cells by counterstaining with hematoxylin (blue). All
analysis settings including thresholds set for weak, inter-
mediate and strong nuclei staining were maintained
throughout the whole study (Additional file 2: Table S1).
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Results
Establishment of reproducible cytarabine resistant
sub-clones from the MCL cell line Z138
The Z138 cell line is originally derived from a MCL
patient with blastoid transformation, and cells carry the
11;14 translocation and overexpress cyclin D1 [18]. The
untreated Z138 cell line, hereafter referred to as Z138-
CytNS (Z138 Cytarabine Naïve Sensitive) is highly
sensitive toward cytarabine and does not survive con-
centrations at, or above 0.5 μM (Fig. 1a).
Z138-CytNS cells were exposed to increasing concen-
trations (0.005–0.3 μM) of cytarabine to investigate and
define the number of days required to induce resistance
upon continuous exposure. After approximately 60 days,
a highly cytarabine resistant sub-clone, Z138-CytR, was
established growing at an unaffected rate in up to 50 μM
cytarabine (Fig. 1b).
With this information at hand, new cell cultures were
initiated with the aim to establish a reproducible model
where resistance could be induced in a time-controlled
a
c
d e
b
Fig. 1 Functional evaluation of established Z138 sub-clones. Growth of (a) wild type, cytarabine naive sensitive (Z138-CytNS) cells and (b) an
in-house developed cytarabine resistant (Z138-CytR) clone in presence of different concentrations of cytarabine, was assessed by trypan blue
exclusion method at indicated time-points. Each data point represents a mean value of duplicates, and error bars show SEM. The data were
normalized to the 0-h time-point. c Schematic overview of the established Z138 sub-clones. Z138-CytNS cells exposed to increasing concentrations
(0–0.2 μM) of cytarabine for 30 days were expanded and frozen as a cell biobank named cytarabine exposed sensitive (Z138-CytES). The frozen cell
biobank was thawed and used for establishment of a cytarabine resistant (Z138-CytR21) sub-clone, by exposing cells to 0.3 μM cytarabine for a period
of 21 days. Biological replicates indicated as #A-C were included. In parallel, Z138-CytES cells cultured in absence of cytarabine for indicated days were
used as controls (CTR). * marks the samples used for gene expression analysis (presented in Fig. 3a). d Assessment of cell proliferation by incorporation
of [methyl-14C]-thymidine indicates that Z138-CytR21 cells remain unaffected until a concentration of 50 μM cytarabine is reached, as also illustrated
by (e) biological replicates. Each data point represents a mean value of triplicates, and error bars show SEM. The data, representing the 48-h time-point,
are normalized to the time-point 0 h
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manner from a permanent source of viable frozen pre-
exposed cells. Thus, Z138-CytNS cells were exposed to
increasing concentrations of cytarabine and when reach-
ing high viability (> 85%) at 0.2 μM, cells were expanded,
without addition of cytarabine, and frozen to establish a
large and renewable pool of cells with defined time to
resistance development. From this pool of frozen cells
(referred to as Z138-CytES), later experiments showed
that complete resistance (defined as unaffected pro-
liferation at the 50 μM cytarabine concentration) repro-
ducibly can be achieved in ~ 21 days upon exposure to
0.3 μM cytarabine. To be able to investigate the differ-
ence in molecular response to cytarabine exposure and
the molecular signature related to resistance develop-
ment, control cells were cultivated in parallel without
cytarabine during the last 21 days. A schematic repre-
sentation of the experimental set-up and designation of
samples at the different time-points of cytarabine
exposure is shown in Fig. 1c. Comparison of cytarabine
resistance in control (Z138-CytES21) and long-term
cytarabine exposed cells (Z138-CytR21) showed that
although control cells can be kept viable in 0.2 μM cytara-
bine (data not shown), they do not proliferate (Fig. 1d).
Further comparison of replicates (n = 3) of cytarabine ex-
posed cells and control cells at different time-points show
a reproducible resistance of cells up to 50 μM, but loss of
proliferation at 500 μM cytarabine (Fig. 1e).
As p53 status is a prognostic factor for patients treated
with cytarabine-containing regimens [19], the TP53 sta-
tus was investigated in both untreated and cytarabine-
treated cells. All samples were shown to contain only
TP53 WT alleles (data not shown). Proliferation was also
investigated and shown to be similar in all three stages
of resistance development (Additional file 2: Figure S1).
Decreased expression of dCK and ENT during adaptation
and development of resistance
It is previously known that cytarabine is dependent on
the transport protein ENT1 to cross the cell membrane
[20], and the dCK enzyme for phosphorylation into the
active ara-CTP [21]. To evaluate the hypothesis that one
of these important components is involved in the resist-
ance development in MCL, we investigated the expres-
sion of the two proteins at various time-points of
cytarabine exposure. Results show that ENT1 levels start
to drop after approximately 7 days of exposure to 0.3 μM
cytarabine, Z138-CytES7 (Fig. 2), but no further decrease
is seen as the resistance fully develop (Z138-CytES14
compared to Z138-CytR21). Analysis of dCK show that
only minor down-regulation is seen during the continuous
exposure to cytarabine, but an abrupt abolishment of dCK
co-occurs with resistance development (Z138-CytES14
compared to Z138-CytR21, Fig. 2). This is consistent in all
three parallel experiments (Additional file 2: Figure S2).
Recovery studies, where Z138-CytR cells completely
lacking dCK expression were cultured in cytarabine-free
medium for up to 8 weeks, did not show any indication
of regained dCK protein expression or activity (data not
shown). Although the selection pressure was merely sus-
tained and not increased over the 21 days separating the
Z138-CytES0 cells from Z138-CytR21 cells (Fig. 1d), the
dCK expression was not completely lost until 21 days of
exposure to 0.3 μM cytarabine. The expression of dCK
was validated through TaqMan probe-based RT-PCR,
where a significant down-regulation of dCK could be
confirmed in both Z138-CytES and Z138-CytR21 com-
pared to Z138-CytNS. No significant change in dCK
mRNA levels was seen comparing cells grown with
(CytR) or without cytarabine (CytES21) for 21 days be-
yond ES cells (Fig. 3). Based on this data, we draw the
conclusion that the strongest association between cytara-
bine resistance and dCK is on protein level.
The results show that complete loss of dCK is crucial
for cytarabine resistance and that cells adapt gradually,
with initial increased viability and later restored/increased
proliferation when exposed to a fixed concentration
of cytarabine.
Re-introduction of dCK in CytR cells restore sensitivity to
high concentrations of cytarabine
To validate the direct effect of dCK on resistance, a tran-
sient re-introduction of dCK in resistant cells was per-
formed. DCK cDNA (see Additional file 1) and a control
vector containing GFP were introduced via nucleofec-
tion. Cell viability was 80–85% 24-48 h after nucleofec-
tion of both control and dCK plasmid (data not shown).
Protein expression was restored to levels correlating to
Z138-CytNS cells (Fig. 4a). Z138-CytR cells where dCK
expression had been transiently re-introduced (dCK+)
were more sensitive to high concentrations of cytarabine,
but the effect was less prominent for concentrations
below 50 μM (Fig. 4b). This may be due to that the
transfection efficiency measured after 24 h was around
65–80% (data not shown) and thus resistant clones, lack-
ing dCK, remained.
Gene expression analyses reveals major changes in
transcription during adaptation, and the key protein SPIB
related to development of resistance
To molecularly investigate resistance development, gene
expression analysis was performed with resistant (Z138-
CytR21) and control cells, from three different time-
points (Z138-CytNS, Z138-CytES, Z138-CytES21 (CTR)).
The microarray data was analysed in order to identify
unique genes and/or gene signatures associated to (i)
adaptation, or (ii) resistance. Upon two group compari-
sons of cytarabine naïve sensitive (Z138-CytNS) and
cytarabine exposed sensitive (Z138-CytES) cells, 68 genes
Freiburghaus et al. BMC Cancer  (2018) 18:466 Page 6 of 17
(Fig. 5a, Additional file 2: Table S3) were found as signifi-
cantly (q < 0.05) deregulated and associated to the adapta-
tion with high viability in presence of 0.2 μM cytarabine.
Further analysis revealed that only minor transcriptional
changes co-occur with the later phase of resistance devel-
opment (Z138-CytES compared to Z138-CytR21). In total,
3 genes; FABP5, SPIB and TCEA3 (Fig. 5b, Additional file
2: Table S3) were found to be significantly (q < 0.05)
deregulated. The upregulation of genes between Z138-
CytES and Z138-CytR could be confirmed with TaqMan
probe based RT-PCR (Fig. 5c), but both here and on pro-
tein level, SPIB showed the highest increase of expression
in Z138-CytR compared to Z138-CytNS cells (Fig. 5d). In
contrast to the mRNA, SPIB protein show increased level
already in the Z138-CytES cells.
Cytarabine resistant cells show increased levels of NF-κB
and IκBα
MCL is known to be dependent on constitutive activa-
tion of NF-κB, and as SPIB has been reported to regulate
this pathway in other lymphomas [22] we investigated
the activity of the pathway in the different subclones. In-
creased activity in the resistant cells was confirmed
through western blot which showed major increase in
both total NF-κB and IκBα in Z138-CytR cells (Fig. 6a).
Of note, re-introduction of dCK into resistant cells using
transient overexpression, decreased the protein levels of
SPIB, NF-κB and IKBα back to the original levels of un-
treated cells (Fig. 6b-c), indicating that dCK not only
affect conversion of the pro-drug to active substance but
also affect molecular pathways of importance for prolif-
eration, differentiation and apoptosis.
Knock-down of SPIB partly restores the sensitivity
towards high doses of cytarabine in resistant cells
To further understand the identified relation between
SPIB upregulation and cytarabine resistance, SPIB was
partly knocked-down using siRNA. SPIB mRNA de-
creased about 50% compared to the control 48 h after
transfection (Fig. 7a). Western blot analysis revealed that
protein levels were consistent with the decrease on
mRNA level, with almost 40% less expression in
knocked-down cells compared to control (Fig. 7b). This
partial silencing decreased the proliferation of resistant
cells with about 25% compared to the control cells in
50 μM cytarabine (Fig. 7c), but dCK protein levels were
not restored. This indicates that SPIB does not directly
regulate dCK.
Z138-CytR cells are cross-resistant to other nucleoside
analogues but sensitive to several clinically relevant
drugs
To investigate the potential cross-resistance of Z138-CytR
cells to other cytostatic compounds, a library of 40 chemo-
therapeutic agents was used to assess proliferation upon
exposure to the substances at four different concentrations.
The relative sensitivity of cytarabine naïve sensitive (Z138-
CytNS) and cytarabine resistant cells (Z138-CytR) was
compared (Additio0nal file 1: Figure S3A-B). Results show
that Z138-CytR, were cross-resistant to all nucleoside ana-
logues evaluated (cladribine, fludarabine and gemcitabine),
defined as < 50% reduction in proliferation, compared to
Fig. 3 Verification of dCK mRNA expression in gene microarray
samples. The relative mRNA expression of dCK was assessed in the
different Z138 subclones using TaqMan probe based RT-PCR and
revealed down-regulation in both Z138-CytES and Z138-CytR cells
compared to Z138-CytNS cells. The data are normalised to the S18
reference gene, and the reference sample, replicate A of the Z138-CytNS
for each run. Bars represent relative quantity ± SEM of three technical
replicates. * = p < 0.05 with statistical significance determined using
the Holm-Sidak method, with alpha = 0.05. All significance is compared
with Z138-CytNS. Each row was analyzed individually, without
assuming a consistent SD
Fig. 2 Assessment of dCK and ENT1 protein expression. Representative western blot analysis of indicated proteins in Z138 sub-clones. CytNS: cytarabine
naive sensitive, CytES: cytarabine exposed sensitive, CytR21: cytarabine resistant, CTR: control, B: replicate B. GAPDH was used as loading control
Freiburghaus et al. BMC Cancer  (2018) 18:466 Page 7 of 17
the DMSO control, at any of the concentrations used
(Additional file 2: Figure S3B, filled dark bars). The resist-
ance to cladribine, fludarabine and gemcitabine was
confirmed in separate experiments with a wider concentra-
tion range (Fig. 8). Wild type cells were sensitive to gemci-
tabine and cladribine, and thus cross-resistance is detected
already at low concentrations (0.01 and 0.1 μM
respectively) while reduction of proliferation after exposure
to fludarabine was seen at or above 1 μM.
Interestingly, comparing the response of cytarabine
naïve sensitive and cytarabine resistant cells to treatment
with 1 and/or 10 μM chemotherapeutic library, eleven
substances were identified to have an anti-proliferative
effect (defined as > 50% reduction in proliferation com-
pared to DMSO control) on both Z138-CytNS and
Z138-CytR cells (Additional file 2: Figure S3, empty
bars). These include topotecan HCl, teniposide, oxalipla-
tin, vincristine, paclitaxel, mitoxantrone hydrochloride,
etoposide, docetaxel, cerubidine and doxorubicin and
are thus of interest for treatment of patients who relapse
on cytarabine-containing regiments.
Histone deacetylase inhibitors have a stand-alone effect
in cytarabine resistant cells and show a weak tendency to
restore cytarabine sensitivity
To evaluate the stand-alone effect of various epigenetic
drugs, a library of 43 epigenetic substances was used to
assess sensitivity in cytarabine resistant cells. Eleven of
the tested reagents from the epigenetic library had a
stand-alone effect (defined as > 50% reduction in prolif-
eration compared to DMSO control) on Z138-CytR cells
at 10 μM (Additional file 2: Figure S4A right, filled dark
bars). Of note, a majority of the effective compounds
were histone deacetylase (HDAC) inhibitors.
For further validation, six compounds (apicidin, M-344,
oxamflatin, scriptaid, trichostatin A and vorinostat) effect-
ive already at 1 μM (Additional file 2: Figure S4A left,
filled dark bars) were selected (BML-281 and NSC-3852
were not commercially available in larger quantities). An
additional HDAC inhibitor, not included in the library
(belinostat) and a negative DMSO control were also in-
cluded in the further evaluation. All substances, except for
the negative control exhibited an inhibitory effect on
Z138-CytR cell proliferation at concentrations above
1 μM (Additional file 2: Figure S4-B).
Similar effects were observed for the cytarabine naïve
sensitive (Z138-CytNS) cells (Additional file 2: Figure S5).
Based on these observations, additional experiments were
performed in order to investigate the potential sensitizing
effect on cytarabine resistant cells. Z138-CytR cells were ex-
posed to a wide range of concentrations for 6 h prior to
addition of cytarabine. A number of the HDAC inhibitors
showed tendencies to induce cytarabine sensitivity in Z138-
CytR cells at their lowest concentrations (0.1–0.5 μM), but
for two of them, the difference between growth with or
without cytarabine was significant also for the DMSO
control, indicating that these results may be false positive
(Fig. 9). Taken the effect of cytarabine alone into account,
belatonin, M-344, trichostatin A and vorinostat stand out
as possible sensitizers. A longer exposure time than 6 h
was not technically feasible, which may have limited the
impact of the epigenetic drugs.
Previous attempts to re-sensitize cells with resistance
to nucleoside analogues include treatment with mela-
tonin, an indolamine that overcome resistance to clofar-
abine by increasing expression of dCK [23]. However, in
our system co-culture with melatonin or hydralazine
could not re-sensitize cells to cytarabine after dCK
down-regulation (data not shown).
Resistant cells show slightly increased sensitivity towards
lenalidomide and ibrutinib
In our search for drugs effective against cytarabine-
resistant cells, both a targeted and library approach was
used. It is well known that both ibrutinib and lenalido-
mide targets the NF-κB pathway, and thus the sensitivity
towards these drugs was assessed. Z138-CytR and Z138-
CytES cells showed significantly increased sensitivity
a b
Fig. 4 Assessment of the effects of re-introduction of dCK into resistant cells. a Western blot analysis of dCK proteins in Z138 sub-clones, 48 h
after introduction of ORF-plasmid via nucleofection. GAPDH was used as loading control. b Normalized proliferation for Z138 cells grown in
cytarabine containing medium, measured by incorporation of [methyl-14C]-thymidine 48 h after introduction of ORF-plasmid via nucleofection.
Each data point represents a mean value of triplicates and error bars show SD. * = p < 0.05 and ** = p < 0.01, using students unpaired t-test
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towards 50 μM ibrutinib compared to Z138-NS,
although at such high concentrations, proliferation is
severely impaired for all subclones (Additional file 2:
Figure S6A). The sensitivity towards lenalidomide was
also significantly increased for both Z138-CytR and Z138-
CytES cells compared to Z138-NS (Additional file 2: Fig-
ure S6B), although at a low magnitude.
Bortezomib treatment prevents resistance development
Bortezomib acts on the NF-κB pathway by preventing the
degradation of IκBα. We could confirm that Z138-CytR
cells were more sensitive to bortezomib concentrations
above 0.005 μM compared to Z138-NS (Fig. 10a-b)
while lower concentrations did not affect proliferation
(Additional file 2: Figure S1B). We hypothesized that
continued exposure to the drug would alter the possi-
bility of the cells to acquire resistance to cytarabine,
either through the decreased degradation of IκBα or
through changes in proteins regulating dCK on the
protein level. To assess this, the cell model was used
to co-treat cells with cytarabine and a low concentra-
tion of bortezomib during the 21 days expected for
resistance to occur (Fig. 10c). The concentration was
selected to avoid effect on proliferation. Co-treatment
with 0.001 μM bortezomib and 0.3 μM cytarabine pre-
vented the expected down-regulation of dCK (Fig. 10d)
and as a result the Z138-CytES cells remained sensitive to-
wards cytarabine (Fig. 10e). Z138-CytR cells remained
dCK negative after long-term exposure (3 weeks) to borte-
zomib, and thus retained their resistance to cytarabine. To
assess whether resistance was prevented or merely delayed
by prolongated proliferation, relative cell number was
monitored throughout the co-treatment study, and no
difference in growth rate could be detected for Z138-
Fig. 5 Heat maps of differentially expressed genes and assessment of their relative expression on qPCR and Western blot. Gene signatures
associated to (a) adaptation (high viability), and (b) resistance (sustained proliferation) upon cytarabine exposure were identified by two-group
comparison (q < 0.05) of Z138-CytNS vs. Z138-CytES, and Z138-CytES vs. Z138-CytR21, respectively. Red and blue colors indicate up- and down-
regulated genes, respectively.
c Assessment of relative SPIB, TCEA3 and FABP5 mRNA expression in Z138-CytNS, Z138-CytES and Z138-CyR cells. The relative mRNA
expressions were assessed in the different Z138 subclones using TaqMan probe based RT-PCR and revealed up-regulation of all three genes for
Z138-CytR cells compared to Z138-CytNS cells, although the difference was most prominent for SPIB. The data are normalized to the S18 refer-
ence gene, and the reference sample Z138-CytNS for each gene. * = p < 0.05 and ** = p < 0.01, with statistical significance determined using the
Holm-Sidak method, with alpha = 0.05. Each row was analyzed individually, without assuming a consistent SD.
d Representative (n = 3) western blot analysis of SPIB, TCEA3 and FABP5 proteins. GAPDH was used as loading control
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CytR cells co-treated with bortezomib compared to
those grown in cytarabine alone (Additional file 2:
Figure S1B).
Moderate to high expression of dCK is common in MCL
diagnostic samples and corresponds well to initial
successful response to cytarabine-containing treatment
Protein levels of dCK were stained for and automatically
scored in 124 diagnostic samples from patients from the
MCL2/3 cohort. Information on intensity and frequency
of positive cells could be combined to define dCK strong
(> 55% positive cells, n = 78), dCK intermediate (< 55%
positive cells, n = 42) and dCK negative samples (> 90%
negative cells, n = 4) (Fig. 11, and Additional file 2:
Table S2). Thus, 120 of 124 patients (97%) had extensive
dCK expression in the diagnostic sample, corresponding
to the overall initial high response to treatment with
cytarabine-containing regiments with 95% of the patients
in the MCL2/3 cohort are progression free 6 months after
inclusion to trial. As the number of dCK negative/weak
patients where low, it was not statistical feasible to evalu-
ate differences in survival.
Discussion
Resistance to cytarabine is a significant clinical problem,
as this agent is part of the backbone of treatment in a
wide range of malignancies, including MCL. Thus, ways
of predicting and possibly prevent cytarabine resistance
are needed. The aim of the present study was to further
explore the mechanisms of cytarabine resistance in
MCL, to identify drugs suitable for treatment of patients
with relapsed/recurrent disease and to identify pre-
ventive measures. To address these important clinical
questions, we have established a unique MCL resistant
model, based on the cell line Z138, in which cytarabine
resistance repetitively in a timely and molecularly repro-
ducibly manner can be induced. This cellular model al-
lows for the first time resistance to be studied over time,
and thus constitute an important research tool, despite
the obvious drawback of being based on a single cell line
It is known that dCK which is a key enzyme in convert-
ing cytarabine to active drug is dependent on functional
p53 [24]. To ensure that the developed resistance was not
caused by introduction of TP53 mutations due to cellular
stress and selection pressure, the resistant cells were se-
quenced and found to contain only TP53 WTalleles.
a
c
b
Fig. 6 Assessment of NF-κB proteins in Z138-CytES and Z138-CytR cells compared to Z138-CytNS cells and with dCK re-expressed. a Due to the
known connection between SPIB and the NF-κB pathway, protein expression of NF-κB and IKBα was assessed with western blot. GAPDH was used
as loading control. b Western blot analysis of NF-κB, IKBα and SPIB protein levels in cells 48 h after transfection with ORF plasmid containing dCK.
GAPDH was used as loading control. c Relative protein expression in the samples, normalized against GAPDH and with the Z138-CytR control sample
set to 1 for each protein. Both western blot and calculated relative protein expression are representative figures of three biological replicates
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b
Fig. 7 Effects of SPIB knock-down on resistant cells. a Conformation of partial silencing of SPIB on gene level. The relative mRNA expression of
SPIB was assessed in the cells using TaqMan probe based RT-PCR and revealed a knock of gene expression with 50% compared to un-knocked
control cells. The data are normalised to the S18 reference gene. b Protein levels of SPIB measured with western blot 48 h after transfection with
siRNA. GAPDH was used as loading control. Representative figure of three biological replicates. c Normalised proliferation for Z138 cells grown in
cytarabine containing medium, measured by incorporation of [methyl-14C]-thymidine 72 h after knock of SPIB using siRNA. Each data point
represents a mean value of triplicates and error bars show SD. * = p < 0.05, using students unpaired t-test
Fig. 8 Evaluation of cross-resistance to common nucleoside analogues. Assessment of Z138-CytNS and Z138-CytR cell proliferation after treatment
of cells for 48 h with different concentrations of four different nucleoside analogues, including cytarabine, gemcitabine, cladribine and fludarabine.
The data are normalized to the 0-h time-point, and visualized as relative to the DMSO vehicle control. Each data point represents mean of three
independent experiments
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Transportation and activation of cytarabine is medi-
ated by several classes of transporters and activating
enzymes, such as ENT [11] and dCK [12], as described
in more detail elsewhere [25]. Using molecular profiling,
we show that in our model, down-regulation of ENT1 is
associated with adaptation to cytarabine exposure, but
no further decrease is seen upon final development of
resistance. Thus, in our model, ENT1 is not the limiting
factor for resistance development, but rather a stand-by
effect related to exposure to cytarabine. Also, previous
studies using MCL cell lines show that there is a correl-
ation between the expression of ENT1 and sensitivity to
nucleoside analogues such as gemcitabine [26]. In child-
hood AML patients, sensitivity towards nucleoside ana-
logues could be linked to ENT1 mRNA levels, with
decreased levels of ENT1 in cytarabine resistant com-
pared to sensitive patients [27]. However, it is not clear
from these studies whether the down-regulation of
ENT1 is a bystander effect, as our results indicate, or
the limiting factor for drug sensitivity.
In the current study, we show that the final step of re-
sistance development is associated with a complete down-
regulation of the dCK protein. To investigate if the cellular
levels of dCK protein is regulated at the transcriptional
Fig. 9 Assessment of epigenetic drug-mediated sensitization of cytarabine resistant cells. Proliferation of Z138-CytR cells exposed to different
concentrations of six epigenetic drugs for 6 hours, prior to addition of 50 μM cytarabine. Several epigenetic drugs showed a tendency to re-sensitize
Z138-CytR to cytarabine, at the lowest concentration (0.1 μM). Each data point represents mean relative proliferation ± SEM of three independent
experiments. * = p < 0.05 and ** = p < 0.01, using students unpaired t-test. The data, collected 30 h after treatment, are normalized to the 0-h time-point
and the R10 medium control (+/− cytarabine)
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level, we performed gene expression analysis followed by
RT-PCR validation. We show that dCK mRNA is down-
regulated upon exposure and adaptation to cytarabine, but
with minor additional down-regulation upon resistance
development, indicating that post-translational modifica-
tion may be involved in the final steps of resistance devel-
opment. The relation between the dCK mRNA level and
enzymatic activity has been explored previously. For ex-
ample, using gemcitabine treatment in tumours of differ-
ent origin such as pancreas and lung, it was shown that
resistance only is predicted by dCK activity and protein
level, and not by dCK mRNA level [28], in agreement with
our data. DCK enzymatic activity is controlled by
phosphorylation at Ser-74 [29], and dephosphorylation
decreases enzyme activity [30]. A more active mutant of
dCK, with a 10,000-fold increased sensitivity to nucleoside
analogues has been created and could be of interest for
suicide gene approaches [10, 31]. Of note, in our hands
forced overexpression of dCK had a direct effect on sensi-
tivity to cytarabine in our model, indicating that protein
levels govern resistance but that post-translational modifi-
cation adjust the level of resistance.
To further molecularly characterize the two distinct
phases of (i) cytarabine adaptation and (ii) resistance
development, global gene expression analysis was per-
formed. Analysis reveals that major changes (68 genes)
a
c
d e
b
Fig. 10 Protein expression of dCK and proliferation of Z138 sub-clones after co-treatment with bortezomib. Growth of cytarabine naive sensitive
(Z138-CytNS) cells, cytarabine exposed sensitive (Z138-CytES) cells and cytarabine resistant (Z138-CytR) cells in presence of (a) no drug or (b)
0.005 μM bortezomib after 24–72 h, measured by incorporation of [methyl-14C]-thymidine. Each data point represents a mean value of triplicates ± SEM.
* = p < 0.05 and ** = p < 0.01, using students unpaired t-test. According to the established model, Z138-CytES cells develop full resistance against
cytarabine after 21 days of exposure to 0.3 μM cytarabine. c Recap of the model from Fig. 1, introducing co-treatment with 0.3 μM cytarabine and
0.001 μM bortezomib, both during resistance development and once resistance have been established. d Western blot analysis of dCK in Z138
sub-clones after 3 weeks of treatment with 0.3 μM cytarabine or co-treatment with 0.3 μM cytarabine and 0.001 μM bortezomib. GAPDH was used as
loading control. Representative figure of three biological replicates. e Growth of cytarabine naive sensitive (Z138-CytNS) cells, cytarabine exposed
sensitive (Z138-CytES) cells and cytarabine resistant (Z138-CytR) cells in presence of 50 μM cytarabine measured by incorporation of [methyl-14C]-thymidine.
Each data point represents a mean value of triplicates ± SEM. * = p < 0.05 and ** = p < 0.01, using students unpaired t-test
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in gene expression could be associated with the initial
adaptation to growth in cytarabine containing media. In
contrast, only a few genes (FABP5P7, FABP5P1, FABP5,
SPIB and TCEA3) showed expression changes upon
final resistance development. Among those genes, SPIB
showed major changes on the protein level. It is known
from previous reports that SPIB is frequently overex-
pressed in diffuse large B cell lymphomas (DLBCL),
and is a poor prognostic factor [22]. Of note, SPIB and
IRF4 have been shown to amplify NF-ĸB signalling by
transactivating CARD11 [32]. SPIB has not previously
been described in relation to MCL and the connection
to increased NF-ĸB activity in our model is of major
interest. NF-ĸB is highly active in MCL and is consid-
ered to be a key feature for the aggressiveness of MCL
[33]. Constitutively active NF-κB in MCL may be
caused by different factors such as, chronic activation
of the B cell receptor (BCR) or mutations in the Toll
like receptor (TLR) signalling pathway. When the acti-
vation is a result of somatic mutations on inhibitors of
the alternative pathway, the activation is unaffected by
BCR inhibitors [4]. To pursue if the increased aggres-
siveness of the resistant cells could be related to en-
hanced NF-ĸB activity, related proteins were
investigated. Analysis showed that the resistant cells
have elevated levels of both NF-ĸB total protein as well
as IκBα, indicating increased engagement of the path-
way in dCKnegative/SPIBhigh cells exhibiting resistance to
cytarabine. Of major interest, forced overexpression of
dCK led to decreased SPIB and NF-ĸB levels showing
for the first time that dCK not only have an impact on
the conversion of pro-drugs into active drugs, but also
contribute to resistance through direct transcriptional
control of pathways involved in proliferation and apop-
tosis. DCK as a key-driver was further pin-pointed by
the fact that knock-down of SPIB did not affect dCK or
NF-ĸB levels, although cytarabine resistance was
slightly affected. Thus, SPIB does not regulate dCK
levels but is likely associated with increased resistance
through other means.
As NF-ĸB seem to play a major role in resistance we
assessed if drugs known to be able to affect NF-ĸB activity,
such as the immune-modulating drug lenalidomide [34]
and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib
[35], had increased activity in the resistant cells. However,
it was only at high concentrations of lenalidomide and
Ibrutinib that the resistant cells had a significant increased
sensitivity to cytarabine treatment.
In order to identify clinically relevant drugs effective
in cytarabine resistant cells, a library of chemothera-
peutic compounds was used. Eleven drugs, some pre-
dominantly used in treatment of solid cancers, and to
less extent in treatment of leukemias and lymphomas,
showed strong anti-proliferative effect on cytarabine
resistant cells. Interestingly, four of the eleven drugs
have already been considered in treatment of MCL,
either as part of standard therapy (doxorubicin and
vincristine) or as part of clinical trials including re-
fractory MCL (mitoxantrone [36] and etoposide [37]).
Also previous studies on cytarabine resistant leukae-
mia cells show that such cells are sensitive to vincris-
tine and mitoxantrone [38], supporting the clinical
usefulness of these drugs for treatment of cytarabine-
resistant disease. Novel drugs that may have a clinical
role for treatment of cytarabine-resistant disease in-
cluded topotecan HCl, teniposide, oxaliplatin, pacli-
taxel, docetaxel and cerubidine.
As expected, cytarabine resistant cells showed cross-
resistance to other nucleoside analogues, including gem-
citabine, cladribine and fludarabine, emphasizing the
specificity of our model, development of nucleoside
analogue-resistant cells and not a general increased drug
resistance [12, 14].
It has been proposed that the down-regulation of dCK
is mediated by epigenetic mechanisms [39, 40] and in
order to evaluate if epigenetic drugs have a potent (i)
stand-alone effect or potentially, (ii) a sensitizing effect,
a library with epigenetic compounds was evaluated. Of
interest, most of the compounds that showed inhibitory
effect on cytarabine resistant cells were HDAC
Fig. 11 Representative immunostainings of dCK. The immunohistochemistry panel shows representative figures of negative/weak, intermediate,
and strong dCK staining assessed by digital scoring using HALO™
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inhibitors. The potential of these compounds to re-
sensitize resistant cells to cytarabine was assessed through
pre-incubation prior to cytarabine exposure. Some of the
compounds showed a minor tendency to increase cytara-
bine sensitivity after pre-treatment with low concentra-
tions of HDAC inhibitors. Potentially, a longer pre-
treatment would have generated a larger impact on cytara-
bine resistance. HDAC inhibitors generally have low tox-
icity and although further pre-clinical studies are needed,
inclusion of such inhibitors in combination with cytara-
bine should be considered.
Our present data pinpoints the importance of dCK for
resistance development, and thus ways of preventing
and restoring dCK activity would have a major clinical
impact for treatment of MCL patients. Several previous
studies have used different approaches to increase dCK
activity and thus revert cytarabine resistance. Among
others, it has been shown that dCK was silenced through
promoter DNA methylation, and that demethylation can
restore dCK levels [39]. However, in our hands neither
decitabine nor hydralazine resulted in restored sensitivity.
From our data, it is clear that dCK activity is governed
by mechanisms at the protein level and we hypothesized
that co-treatment with bortezomib, a proteasome inhibi-
tor, could prevent down-regulation of dCK and develop-
ment of resistance. Bortezomib, is a reversible proteasome
inhibitor, primarily used in MCL as part of combinatorial
therapy and approved for treatment of relapsed MCL [41].
Inhibition of the NF-κB pathway, leading to apoptosis, has
been reported as a major mechanism of action for borte-
zomib [42] and that correlates well with our model, show-
ing increased sensitivity to bortezomib (at concentrations
above 0.005 μM) in resistant cells compared to sensitive.
Interestingly, the effects of bortezomib were much more
prominent than for both lenalidomide and ibrutinib. The
difference may partly be explained by the fact that the tar-
gets of bortezomib affects proteins more directly involved
in NF-κB activation and regulation. However, being a pro-
teasome inhibitor the action of bortezomib is not specific
for the NF-κB pathway and several other cellular targets
and pathways may be affected. Co-treatment with borte-
zomib prevented the development of cytarabine resistance
and constitute a very attractive complement to cytarabine
treatment in clinical protocols. Proliferation was assessed
and no difference in growth rate was observed between
cells co-cultured with both bortezomib (at 0.001 μM) and
cytarabine compared to cells treated with cytarabine
alone, ruling out the possibility that the resistance was
prevented due to decreased proliferation. To our know-
ledge, this is the first time that it has been shown that
cytarabine resistance can be prevented, which is of major
clinical importance. As bortezomib is an already approved
drug, implementation into the clinic should be rapid. It
should be noted however, that the concentrations used in
our study is in the low-end of the bortezomib serum levels
measured in patients treated within current dosing regi-
ments [43]. Previous studies have demonstrated a synergy
effect of bortezomib and cytarabine both in vitro and in
individual case reports [44] and also as part of a small
combinatorial therapy trial [45]. A clinical trial is currently
ongoing, where bortezomib was combined with cytarabine
for treatment of relapse patients, and results may shed
light on the efficacy of this co-treatment [46]. Diagnostic/
pre-treatment levels of dCK have in a previous study been
shown to predict in vivo gemcitabine sensitivity in human
tumour xenografts (pancreas, colon, ovarian cancer) [28].
Thus, using a cohort of patients treated with the combina-
torial Nordic MCL2/3 protocol, where 95% of the patients
are progression free ≥6 months after therapy including
high-dose cytarabine, we investigated the diagnostic levels
of dCK. The dCK levels were automatically scored to
identify both frequency of positive tumour cells, but also
intensity of nuclear dCK levels. Ninety seven percent of
the patients showed high or intermediate expression of
dCK, corresponding to the high clinical response to the
cytarabine-containing combinatorial protocol. Thus, the
number of dCK negative/weak patients were too few to
evaluate impact on survival. Today, material from relapsed
MCLs is not available but constitute an important work
material to study to validate our finding of down-regulation
of dCK and development of cytarabine resistance.
Conclusions
With the aim to understand the molecular mechanisms
of cytarabine resistance in MCL and identify substances
that can be used to treat refractory and relapsed disease,
we have established a cytarabine resistant in vitro model.
This model has been used to show that cytarabine resist-
ance occurs as a result of complete dCK down-
regulation and that resistant cells show increased SPIB
and NF-κB. We show for the first time that dCK not
only is associated with phosphorylation of pro-drugs,
but also directly affect SPIB and NF-κB levels in resist-
ant cells, and thus have impact on pathways crucial for
proliferation and resistance to apoptosis. The use of che-
motherapeutic and epigenetic compound libraries has
pin-pointed clinically relevant drugs that can be used to
treat resistant disease. Of note, co-treatment with borte-
zomib prevented down-regulation of dCK and develop-
ment of resistance and may have an immediate clinical
impact on the treatment of MCL patients. The results
that were based on a single cell line have generated hy-
pothesis regarding how cytarabine-resistance may be
avoided and targeted in the clinic, and should be further
validation in clinical material such as collection of re-
lapsed samples and samples from clinical studies with
combined use of bortezomib and cytarabine.
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